BioMarin Prepares To Launch Roctavian For Hemophilia In An Uncertain Environment

 
• By Jessica Merrill

The company lowered revenue guidance due to COVID-19, but announced a new brand name, Roctavian, for its hemophilia A gene therapy, which it said remains on track for FDA approval later this year.

Selected focus on nurse hand preparing a saline tube for infuse patient arm in the hospital. Patient is on drip receiving saline solution.
Infused medicines are facing some challenges because of COVID-19 • Source: Shutterstock

BioMarin Pharmaceutical Inc. is still on track to launch the first gene therapy for hemophilia A in the US later this year, but acknowledged during its first quarter sales and earnings call on 29 April that the commercial dynamics are uncertain because of the COVID-19 outbreak.

Management unveiled a new brand name for valoctocogene roxaparvovec, which will be marketed as Roctavian

More from Earnings

More from Business